Rejection of Phase 2 Clinical Trial Plan for COVID-19 Vaccine AdCLD-CoV19-1 LP.8.1
- The Ministry of Food and Drug Safety rejected the IND for Phase 2 clinical trial of COVID-19 vaccine AdCLD-CoV19-1 LP.8.1 due to insufficient data.
- The company will review the rejection reasons and establish a response plan, including potential appeal.
- The statistical probability of final approval for clinical trial drugs is about 10%, indicating commercialization uncertainty.
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Major Management Matters Related to Investment Decision (Rejection of Application for Approval of Phase 2 Clinical Trial Plan of COVID-19 Preventive Vaccine AdCLD-CoV19-1 LP.8.1 (IND))
- Company: Cellid (299660)
- Submission: Cellid Co., Ltd.
- Receipt: 05-08-2026
- Under KRX KOSDAQ Market Division